GLOBAL BLOOD THERAPEUTICS Stock News

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

The FDA has granted accelerated approval to Global Blood Therapeutics Inc''s (NASDAQ: GBT ) supplemental application seeking approval for Oxbryta (voxelotor) tablets for sickle cell disease (SCD) in children ages 4 to less than 12 years. This approval expands the previously approved use of Full story available on Benzinga.com

European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) p

European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease HbS polymerization and red blood cell sickling drive deterioration of red blood cell health and result in hemolysis and hemolytic anemia, leading to inflammation, organ damage and early death SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta ® ( voxelotor) tablets for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). Oxbryta, an oral treatment taken once daily, would be the first medicine available in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular cause of sickling and destruction of red blood cells in SCD.

Wall Street analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report ($1.14) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Twelve analysts have issued estimates for Global Blood Therapeutics earnings, with the lowest EPS estimate coming in at ($1.31) and the highest estimate coming in at ($0.94). Global Blood []

Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering.  The offering size was increased from the previously announced offering siz

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the notes) in a private offering (the offering) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act). The offering size was increased from the previously announced offering size of $250.0 million aggregate principal amount of notes. GBT also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $45.0 million aggregate principal amount of notes (the additional notes). The sale of the notes to the initial purchasers is expected to close on December 17, 2021, subject to customary closing conditions, and is expected to result in approximately $290.4 million (or approximately $334.1 million if the initial purchasers exercise their option to purchase additional notes in full) in net proceeds to GBT after deducting the initial purchasers discounts and commissions and the estimated offering expenses payable by GBT.

Investors aren't impressed with the company's latest financing move.

The GLOBAL BLOOD THERAPEUTICS, INC. POLITICAL ACTION COMMITTEE (GBT PAC) successfully filed their F1N with a confirmation ID of FEC-1551570 *********CommitteeId: C00788661 | FilingId: 1551570 | FormType: F1N | CoverageFrom: | CoverageThrough: | ReportType: *********

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). GBT also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of notes (the “additional notes”). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The stock price of Global Blood Therapeutics Inc (NASDAQ: GBT) increased by 5.33% in the most recent trading session. This is why it happened.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) shares saw unusually-high trading volume on Monday . Approximately 31,713 shares changed hands during trading, a decline of 97% from the previous sessions volume of 1,096,170 shares.The stock last traded at $28.00 and had previously closed at $27.59. GBT has been the topic of several research reports. Jefferies Financial Group []